Medtronic leads in FDA Class I recalls for 2013

Medtronic ($MDT) generated more Class I recalls than any of its device company rivals in 2013. The FDA assigns that status--its most serious label--when problems behind a product can cause serious injury or death.

Medical Device and Diagnostic Industry compiled FDA data and found that Minnesota-based Medtronic generated 6 Class I recalls during the year. The recalls involved issues with a wide range of products, including guidewires, endotracheal tubes, dystonia therapy and deep brain stimulation lead kits, infusion pumps and insulin infusion sets.

Johnson & Johnson ($JNJ), GE Healthcare ($GE), CareFusion ($CFN) and Hospira ($HSP) rounded out the top 5, according to the story.

FierceMedicalDevices could not successfully reach Medtronic for comment prior to publication.

As Medical Device and Diagnostic Industry reported, Johnson & Johnson and GE Healthcare both landed on the list with 5 Class I recalls, tying for second place. J&J was dogged by problems with insulin infusion pumps, vena cava filters, a blood glucose monitoring system and other products. GE dealt with Class I recalls involving nuclear imaging systems, devices that help enable ventilation, resuscitation systems, parts for a breathing system and an incubator.

San Diego-based CareFusion and Hospira tied for third place with four Class I recalls each. CareFusion faced a recall involving a ventilator and three for a PC unit, and Illinois-based Hospira dealt with three separate recalls for a key infusion system. Separately, Hospira also confronted a recall involving some of its blood sets, which are used to administer blood and blood products to patients.

Overall, the FDA handled 176 Class I recalls in 2013, the story noted.

- read the full MD+DI story

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.